President Trump yesterday issued a new executive order that seeks to lower prescription drug prices. The order directs the Secretary of Health and Human Services to test a “most-favored-nation” pricing model for Part B, and some Part D, drugs.

The concept is similar to the Centers for Medicare & Medicaid Services’ International Pricing Index model from October 2018, which resulted in AHA concerns about its potential impact on the 340B program.

“While the AHA will review the specifics of any international pricing index model closely, our primary concern with the previously proposed model was its potential to undermine the important discounts that drug companies are currently required to provide under the 340B drug savings program to certain health care providers,” said AHA President and CEO Rick Pollack. “This change could potentially put vulnerable communities and patients at risk, especially those hospitals and health systems that serve vulnerable populations. Instead, we continue to ask the Administration and CMS to hold harmless those who benefit from reduced drug costs through the 340B program from any adverse impact resulting from this new initiative.”

Related News Articles

Headline
The House Committee on Oversight and Reform today launched a two-day hearing to examine pricing practices for some of the nation’s costliest drugs.…
Headline
The Food and Drug Administration yesterday released a final rule allowing states, territories and Indian tribes to establish programs to import certain…
Headline
A new study demonstrates the cost to the U.S. health care system from an anti-competitive tactic known as “product hopping,” which involves a brand name drug…
Headline
President Trump Friday signed three executive orders aimed at lowering the price of prescription drugs, with actions targeting federally qualified health…
Headline
The Campaign for Sustainable Rx Pricing, for which AHA is a founding member, today launched a petition and digital ad urging drug companies to suspend their “…
Headline
List prices for branded pharmaceutical products in the United States increased 159% between 2007 and 2018, an average of 9.1% per year, according to a study…